Austin, TX, May 23, 2025 (GLOBE NEWSWIRE) -- Outliyr, a performance health brand known for combining modern biohacking with ...

Chris Taves, Chair of MediPharm, commented: “The troubling fact pattern involving three of the Dissident Nominees raises several red flags. The MediPharm Board urges its shareholders to exercise a ...

U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical tri ...

(Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, announces its strategic plans to capitalize on the growth of Yerbae Brands Corp. (“Yerbae”) after ...

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the ...

The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in the United ...

Mirdametinib is approved in the U.S. for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) ...

BriaCell’s Phase 2 study also achieved a Clinical Benefit Rate (CBR) of 61%, outperforming ASCENT (40%) and TROPiCS-02 (34%), and an Objective Response Rate (ORR) of 14%, which matched or exceeded the ...

GN Store Nord A/S hereby announces that on May 22, 2025, pursuant to Section 38 (1) and Section 39 (1) of the Danish Capital Markets Act, it received a notification from BlackRock, Inc. stating that ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ...

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Outlook Therapeutics are expected to be approximately $13.0 million.